Catalyst Pharmaceuticals (CPRX) Research & Development (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Research & Development of $2.7 million for Q1 2026, up 47.26% on a QoQ basis from $1.8 million in Q4 2025, and down 31.54% year-over-year from $3.9 million in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Research & Development (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- Quarterly Research & Development fell 31.54% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 17.71% YoY) and the FY2025 annual result came in at $12.7 million, changed 0.48% from the prior year.
- Research & Development was $2.7 million for Q1 2026 at Catalyst Pharmaceuticals, up from $1.8 million in the prior quarter.
- Across five years, Research & Development topped out at $83.7 million in Q3 2023 and bottomed at $1.8 million in Q4 2025.
- A 5-year average of $8.3 million and a median of $3.6 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 906.76% — and 2024, when it slumped 96.07%.
- Catalyst Pharmaceuticals' Research & Development stood at $4.1 million in 2022, then slumped by 51.82% to $2.0 million in 2023, then jumped by 92.6% to $3.8 million in 2024, then sank by 52.42% to $1.8 million in 2025, then jumped by 47.26% to $2.7 million in 2026.
- Business Quant data shows CPRX's Research & Development at $2.7 million in Q1 2026, $1.8 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.66 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 4.36 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 83.66 Mn |
| Jun 30, 2023 | 3.95 Mn |
| Mar 31, 2023 | 3.56 Mn |
| Dec 31, 2022 | 4.09 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 3.98 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 4.99 Mn |
| Sep 30, 2021 | 4.49 Mn |
| Jun 30, 2021 | 4.45 Mn |